

REVANCE[®]

Revance to Participate in the William Blair 42nd Annual Growth Stock Conference

May 23, 2022

NASHVILLE, Tenn.--(BUSINESS WIRE)--May 23, 2022-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the William Blair 42nd Annual Growth Stock Conference, taking place June 6-9, in Chicago. Chief Executive Officer, Mark Foley, is scheduled to present on Monday, June 6, at 2:00 p.m. CT / 3:00 p.m. ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for 90 days.

About Revance Therapeutics, Inc.

Revance is a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation, long-acting neuromodulator product, DaxibotulinumtoxinA for Injection. Revance has successfully completed Phase 3 clinical programs for DaxibotulinumtoxinA for Injection in glabellar (frown) lines, for which the company is currently pursuing U.S. regulatory approval, and in cervical dystonia. Revance is also evaluating DaxibotulinumtoxinA for Injection in adult upper limb spasticity. Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA[®] Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the OPUL[™] Relational Commerce Platform. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX[®], which if approved, would be the first and only generic biosimilar to Botox[®] and Botox[®] Cosmetic. For more information or to join our team visit us at www.revance.com.

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Resilient Hyaluronic Acid[®] and RHA[®] are trademarks of TEOXANE SA.

BOTOX[®] is a registered trademark of Allergan, Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220523005368/en/): <https://www.businesswire.com/news/home/20220523005368/en/>

Investors

Revance Therapeutics, Inc.:

Jessica Serra, 626-589-1007

jessica.serra@revance.com

or

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

laurence@gilmartinir.com

Media

Revance Therapeutics, Inc.:

Sara Fahy, 949-887-4476

sfahy@revance.com

Source: Revance Therapeutics, Inc.